SAN DIEGO

圣迭戈

,

，

July 16, 2026

2026年7月16日

/PRNewswire/ -- Inhibrx Biosciences, Inc. ('Inhibrx' or the 'Company') (Nasdaq:

/PRNewswire/ -- Inhibrx Biosciences, Inc.（“Inhibrx”或“公司”）（纳斯达克：

INBX

收件箱

), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the 'Second Amendment') to the Loan and Security Agreement, as amended (the 'Amended LSA') with Oxford Finance LLC ('Oxford,' together with certain of its affiliates party thereto, the 'Lenders'), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to $500.0 million (the 'Credit Facility')..

），一家专注于开发新型生物治疗候选药物的临床阶段生物制药公司，今日宣布其与牛津金融有限责任公司（“Oxford”，连同其参与该协议的某些关联公司，统称“贷款方”）签订了经修订的《贷款与安全协议》（“经修订的LSA”）的第二修正案（“第二修正案”）。根据该修正案，贷款方将融资额度扩大至最高本金总额5亿美元（“信贷设施”）。

The Second Amendment provides for an additional tranche, in an aggregate principal amount of up to $325.0 million in gross proceeds, (i) $100.0 million of which was funded upon execution of the Second Amendment (the 'Term C Loan') and (ii) up to an additional $225.0 million of which may be funded in increments of $50.0 million or more upon the Company's request and at the Lenders' sole discretion (the 'Term D Loan').

第二修正案规定增设一批贷款，总本金金额对应的毛收益最高可达3.25亿美元，其中：(i) 1亿美元在第二修正案签署时已提供资金（“C期贷款”）；(ii) 其余最高2.25亿美元可根据公司请求并在贷款人全权酌情决定下，以每笔5,000万美元或以上的增量提供资金（“D期贷款”）。

Prior to the Second Amendment, the Company had drawn $175.0 million under the Credit Facility..

在第二修正案之前，该公司已在信贷安排下提取了1.75亿美元。

In connection with the funding of the Term C Loan, the Company issued to the Lenders warrants to purchase 21,457 shares of the Company's common stock (the 'Term C Warrants') at a strike price of $93.21 per share, equal to 2% of the value of the Term C Loan. The Term C Warrants are immediately exercisable, and the exercise period will expire 10 years from the date of issuance..

就C期贷款的融资事宜，公司向贷款方发行了认股权证，允许其以每股93.21美元的行权价格购买公司21,457股普通股（“C期权权证”），该金额相当于C期贷款价值的2%。C期权权证可立即行权，行权期将于发行之日起10年后届满。

'We are pleased to expand our partnership with Oxford, which reflects their continued confidence in our clinical pipeline,' said Kelly Deck, Chief Financial Officer of Inhibrx. 'We are very excited about the trajectory of ozekibart (INBRX-109) and INBRX-106 and this capital infusion allows us to maintain full momentum on the advancement of both programs as we await key upcoming data readouts.'.

Inhibrx首席财务官Kelly Deck表示：“我们很高兴能够扩大与牛津大学的合作，这反映了他们对我们临床产品管线的持续信心。我们对ozekibart（INBRX-109）和INBRX-106的发展轨迹感到非常兴奋，此次资金注入使我们能够在等待关键即将公布的数据结果的同时，保持推进这两个项目的全面势头。”

About Inhibrx Biosciences, Inc.

关于 Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms.

Inhibrx Biosciences 是一家处于临床阶段的生物制药公司，专注于开发广泛的新型生物治疗候选药物管线。Inhibrx Biosciences 利用多样化的蛋白质工程方法，以满足复杂靶点和疾病生物学的特定需求，其中包括其专有的蛋白质工程平台。

Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc.

Inhibrx Biosciences 于2024年1月成立，为 Inhibrx, Inc. 的直接全资子公司。在向赛诺菲公司（Sanofi S.A.）出售 Inhibrx, Inc. 及 INBRX-101 项目之前，Inhibrx Biosciences 通过由 Inhibrx, Inc. 实施的一系列内部重组交易，收购了某些公司基础设施及其他资产和负债。

Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences' current clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function.

Inhibrx, Inc. 还完成了向其普通股股东分派 Inhibrx Biosciences 92% 的已发行及流通股份。在上述交易完成后，Inhibrx Biosciences 目前的临床候选治疗产品管线包括 ozekibart（INBRX-109）和 INBRX-106，两者均采用多价格式，其精确价态可以以靶点为中心的方式进行优化，从而介导我们认为最适宜的激动剂功能。

For more information, please visit .

更多信息，请访问。

www.inhibrx.com

www.inhibrx.com

.

。

Forward-Looking Statements

前瞻性陈述

Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: the financial capacity available under the Credit Facility, including the potential for Inhibrx to draw down an additional $225.0 million, future clinical development of Inhibrx's therapeutic candidates, including statements regarding the timing of future data readouts, and evaluations and judgments regarding Inhibrx's strategic flexibility, cash position and balance sheet.

Inhibrx 提醒您，本新闻稿中涉及非历史事实的陈述属于前瞻性陈述。这些陈述基于 Inhibrx 当前的信念和预期。这些前瞻性陈述包括但不限于以下方面的陈述：信贷便利下可用的财务能力，包括 Inhibrx 可能额外提取 2.25 亿美元的潜力；Inhibrx 治疗候选产品的未来临床开发，包括关于未来数据公布时间的陈述；以及对 Inhibrx 战略灵活性、现金状况和资产负债表的评估与判断。

Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials a.

实际结果可能因Inhibrx业务中固有的风险和不确定性而与本新闻稿中所述内容存在差异，包括但不限于以下方面的风险和不确定性：其临床前研究、临床试验以及研发项目的启动、时机、进展和结果；其将候选治疗药物推进至临床试验并成功完成试验的能力；其对临床试验初步、中期或前期数据的解读，包括对疾病控制和疾病反应的解读；监管申报和批准的时间或可能性；若获得批准，其候选治疗药物的成功商业化；若获得批准，其候选治疗药物的定价、保险覆盖和报销情况；其利用技术平台生成并推进更多候选治疗药物的能力；其商业模式及针对业务和候选治疗药物的战略计划的实施；其为临床试验成功生产候选治疗药物的能力。

Investor and Media Contact:

投资者与媒体联系人：

Kelly Deck, CFO

凯莉·戴克，首席财务官

[email protected]

[email protected]

858-795-4260

858-795-4260

SOURCE Inhibrx Biosciences, Inc.

来源：Inhibrx Biosciences, Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示